Unternehmens-Analyse: Bayer

Zusammenfassung

Bayer AG (BAYN, EUR reporting) is a diversified life-science group with three operating divisions: Crop Science (seeds, traits, crop protection and digital farming), Pharmaceuticals (specialty and primary care medicines), and Consumer Health (OTC). The core competency is large-scale R&D and global commercialization across regulated markets, supported by manufacturing, agronomic/medical evidence generation, and broad distribution. The investment case remains dominated by (1) operational execution in Crop Science and Pharma amid mixed end-markets and patent cycles, and (2) the pace and cost of U.S. litigation cash outflows. Market position: Bayer is a top-tier global crop inputs provider and a meaningful global pharma player with several growth brands (e.g., Nubeqa and Kerendia) offsetting LOEs/competition in legacy products. Competitive advantages include scale in agricultural R&D and germplasm/traits, established regulatory capabilities, and global commercial reach. Key structural disadvantages versus peers are elevated legal overhang and leverage, which raise the cost of capital and constrain optionality. Recent developments (last ~90 days): In Q2 2026, Bayer reported Group sales of €10.872bn (+2.2% currency/portfolio-adjusted) and EBITDA before special items of €2.144bn (+1.9%). Core EPS in Q2 was €0.95 (down 16.7% YoY). Free cash flow in Q2 was -€371m, with management attributing the deterioration largely to higher litigation-related payments. Management reiterated the 2026 currency-adjusted Group outlook (sales/earnings/FCF) and lowered the year-end net financial debt expectation to €29–30bn (from €32–33bn), explicitly reflecting a planned minority equity investment by Apollo expected to close in H2 2026. Management also highlighted recent capital markets access (including a USD bond placement) as part of liquidity management. Financial metrics (EUR): Profit-based multiples are currently less informative due to special items and litigation-related charges; market data providers show elevated/volatile P/E levels. On an enterprise basis, third-party valuation snapshots indicate EV/EBITDA in the high-single-digit range (provider-dependent, date-stamped). Operationally, Bayer’s reported Q2 2026 EBITDA margin before special items was ~19.7% at Group level (per half-year reporting). Outlook (short/medium term): Near-term performance hinges on Crop Science earnings delivery and continued ramp of newer pharma brands while managing declines in Xarelto/Eylea. The medium-term equity narrative depends on demonstrable reduction in litigation cash uncertainty and sustained deleveraging (including execution of the Apollo transaction and free cash flow normalization once settlement payments abate). Management’s reaffirmed 2026 guidance and reduced net-debt target are supportive, but cash conversion remains pressured by litigation payments in 2026.

Key Takeaways

1. Q2 2026 showed modest top-line growth (+2.2% currency/portfolio-adjusted) with EBITDA before special items up +1.9%, but core EPS declined to €0.95 (down 16.7% YoY).
2. Cash generation remains the key constraint: Q2 free cash flow was -€371m, with management citing higher litigation-related payments as a major driver.
3. Bayer reaffirmed its 2026 currency-adjusted outlook and reduced expected year-end net financial debt to €29–30bn (from €32–33bn), reflecting the planned Apollo minority equity investment expected to close in H2 2026.
4. Pharma mix is bifurcated: growth brands (e.g., Nubeqa/Kerendia) are expanding, while legacy products (e.g., Xarelto/Eylea) face patent/competitive pressure, shaping divisional earnings trajectory.
5. Valuation screens show high sensitivity to normalization assumptions; EV/EBITDA is in high-single digits on major data platforms, while P/E appears elevated/unstable due to special items and earnings volatility.

Action-Ideen

Contrarian Insights

• • The most investable near-term signal may be balance-sheet mechanics rather than divisional growth: management’s explicit reduction of the 2026 net-debt target to €29–30bn (from €32–33bn) tied to the Apollo minority equity investment could matter more for equity risk premium than incremental quarterly margin changes.
• • Consensus focus often centers on litigation as a binary outcome, but the more measurable driver for valuation may be the trajectory of litigation-related cash payments versus operating cash flow. Q2’s negative free cash flow (-€371m) highlights that even with stable EBITDA, cash timing can dominate equity outcomes.